img

Global Poxviridae Infections Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Poxviridae Infections Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Poxviridae Infections Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Poxviridae Infections Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Poxviridae Infections Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Poxviridae Infections Drug key manufacturers include Bavarian Nordic A/S, BioFactura, Inc., CEL-SCI Corporation, Chimerix, Inc., China Biologic Products, Inc., CJ HealthCare Corp., EpiVax, Inc., N & N Pharmaceuticals Inc. and SIGA Technologies, Inc., etc. Bavarian Nordic A/S, BioFactura, Inc., CEL-SCI Corporation are top 3 players and held % sales share in total in 2022.
Poxviridae Infections Drug can be divided into CJ-40011, 24a, BA-368 and Others, etc. CJ-40011 is the mainstream product in the market, accounting for % sales share globally in 2022.
Poxviridae Infections Drug is widely used in various fields, such as Hospital, Clinic and Others,, etc. Hospital provides greatest supports to the Poxviridae Infections Drug industry development. In 2022, global % sales of Poxviridae Infections Drug went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Poxviridae Infections Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Bavarian Nordic A/S
BioFactura, Inc.
CEL-SCI Corporation
Chimerix, Inc.
China Biologic Products, Inc.
CJ HealthCare Corp.
EpiVax, Inc.
N & N Pharmaceuticals Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.
Segment by Type
CJ-40011
24a
BA-368
Others

Segment by Application


Hospital
Clinic
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Poxviridae Infections Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Poxviridae Infections Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Poxviridae Infections Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Poxviridae Infections Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Poxviridae Infections Drug introduction, etc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Poxviridae Infections Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Poxviridae Infections Drug Market Overview
1.1 Poxviridae Infections Drug Product Overview
1.2 Poxviridae Infections Drug Market Segment by Type
1.2.1 CJ-40011
1.2.2 24a
1.2.3 BA-368
1.2.4 Others
1.3 Global Poxviridae Infections Drug Market Size by Type
1.3.1 Global Poxviridae Infections Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Poxviridae Infections Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Poxviridae Infections Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Poxviridae Infections Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Poxviridae Infections Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Poxviridae Infections Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Poxviridae Infections Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Poxviridae Infections Drug Sales Breakdown by Type (2018-2024)
2 Global Poxviridae Infections Drug Market Competition by Company
2.1 Global Top Players by Poxviridae Infections Drug Sales (2018-2024)
2.2 Global Top Players by Poxviridae Infections Drug Revenue (2018-2024)
2.3 Global Top Players by Poxviridae Infections Drug Price (2018-2024)
2.4 Global Top Manufacturers Poxviridae Infections Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Poxviridae Infections Drug Market Competitive Situation and Trends
2.5.1 Poxviridae Infections Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Poxviridae Infections Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Poxviridae Infections Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Poxviridae Infections Drug Market
2.8 Key Manufacturers Poxviridae Infections Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Poxviridae Infections Drug Status and Outlook by Region
3.1 Global Poxviridae Infections Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Poxviridae Infections Drug Historic Market Size by Region
3.2.1 Global Poxviridae Infections Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Poxviridae Infections Drug Sales in Value by Region (2018-2024)
3.2.3 Global Poxviridae Infections Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Poxviridae Infections Drug Forecasted Market Size by Region
3.3.1 Global Poxviridae Infections Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Poxviridae Infections Drug Sales in Value by Region (2024-2034)
3.3.3 Global Poxviridae Infections Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Poxviridae Infections Drug by Application
4.1 Poxviridae Infections Drug Market Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Poxviridae Infections Drug Market Size by Application
4.2.1 Global Poxviridae Infections Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Poxviridae Infections Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Poxviridae Infections Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Poxviridae Infections Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Poxviridae Infections Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Poxviridae Infections Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Poxviridae Infections Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Poxviridae Infections Drug Sales Breakdown by Application (2018-2024)
5 North America Poxviridae Infections Drug by Country
5.1 North America Poxviridae Infections Drug Historic Market Size by Country
5.1.1 North America Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Poxviridae Infections Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Poxviridae Infections Drug Sales in Value by Country (2018-2024)
5.2 North America Poxviridae Infections Drug Forecasted Market Size by Country
5.2.1 North America Poxviridae Infections Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Poxviridae Infections Drug Sales in Value by Country (2024-2034)
6 Europe Poxviridae Infections Drug by Country
6.1 Europe Poxviridae Infections Drug Historic Market Size by Country
6.1.1 Europe Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Poxviridae Infections Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Poxviridae Infections Drug Sales in Value by Country (2018-2024)
6.2 Europe Poxviridae Infections Drug Forecasted Market Size by Country
6.2.1 Europe Poxviridae Infections Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Poxviridae Infections Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Poxviridae Infections Drug by Region
7.1 Asia-Pacific Poxviridae Infections Drug Historic Market Size by Region
7.1.1 Asia-Pacific Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Poxviridae Infections Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Poxviridae Infections Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Poxviridae Infections Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Poxviridae Infections Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Poxviridae Infections Drug Sales in Value by Region (2024-2034)
8 Latin America Poxviridae Infections Drug by Country
8.1 Latin America Poxviridae Infections Drug Historic Market Size by Country
8.1.1 Latin America Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Poxviridae Infections Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Poxviridae Infections Drug Sales in Value by Country (2018-2024)
8.2 Latin America Poxviridae Infections Drug Forecasted Market Size by Country
8.2.1 Latin America Poxviridae Infections Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Poxviridae Infections Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Poxviridae Infections Drug by Country
9.1 Middle East and Africa Poxviridae Infections Drug Historic Market Size by Country
9.1.1 Middle East and Africa Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Poxviridae Infections Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Poxviridae Infections Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Poxviridae Infections Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Poxviridae Infections Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Poxviridae Infections Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Bavarian Nordic A/S
10.1.1 Bavarian Nordic A/S Company Information
10.1.2 Bavarian Nordic A/S Introduction and Business Overview
10.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Bavarian Nordic A/S Poxviridae Infections Drug Products Offered
10.1.5 Bavarian Nordic A/S Recent Development
10.2 BioFactura, Inc.
10.2.1 BioFactura, Inc. Company Information
10.2.2 BioFactura, Inc. Introduction and Business Overview
10.2.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 BioFactura, Inc. Poxviridae Infections Drug Products Offered
10.2.5 BioFactura, Inc. Recent Development
10.3 CEL-SCI Corporation
10.3.1 CEL-SCI Corporation Company Information
10.3.2 CEL-SCI Corporation Introduction and Business Overview
10.3.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 CEL-SCI Corporation Poxviridae Infections Drug Products Offered
10.3.5 CEL-SCI Corporation Recent Development
10.4 Chimerix, Inc.
10.4.1 Chimerix, Inc. Company Information
10.4.2 Chimerix, Inc. Introduction and Business Overview
10.4.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Chimerix, Inc. Poxviridae Infections Drug Products Offered
10.4.5 Chimerix, Inc. Recent Development
10.5 China Biologic Products, Inc.
10.5.1 China Biologic Products, Inc. Company Information
10.5.2 China Biologic Products, Inc. Introduction and Business Overview
10.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 China Biologic Products, Inc. Poxviridae Infections Drug Products Offered
10.5.5 China Biologic Products, Inc. Recent Development
10.6 CJ HealthCare Corp.
10.6.1 CJ HealthCare Corp. Company Information
10.6.2 CJ HealthCare Corp. Introduction and Business Overview
10.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 CJ HealthCare Corp. Poxviridae Infections Drug Products Offered
10.6.5 CJ HealthCare Corp. Recent Development
10.7 EpiVax, Inc.
10.7.1 EpiVax, Inc. Company Information
10.7.2 EpiVax, Inc. Introduction and Business Overview
10.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 EpiVax, Inc. Poxviridae Infections Drug Products Offered
10.7.5 EpiVax, Inc. Recent Development
10.8 N & N Pharmaceuticals Inc.
10.8.1 N & N Pharmaceuticals Inc. Company Information
10.8.2 N & N Pharmaceuticals Inc. Introduction and Business Overview
10.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Products Offered
10.8.5 N & N Pharmaceuticals Inc. Recent Development
10.9 SIGA Technologies, Inc.
10.9.1 SIGA Technologies, Inc. Company Information
10.9.2 SIGA Technologies, Inc. Introduction and Business Overview
10.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 SIGA Technologies, Inc. Poxviridae Infections Drug Products Offered
10.9.5 SIGA Technologies, Inc. Recent Development
10.10 Takeda Pharmaceutical Company Limited
10.10.1 Takeda Pharmaceutical Company Limited Company Information
10.10.2 Takeda Pharmaceutical Company Limited Introduction and Business Overview
10.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Products Offered
10.10.5 Takeda Pharmaceutical Company Limited Recent Development
10.11 Tonix Pharmaceuticals Holding Corp.
10.11.1 Tonix Pharmaceuticals Holding Corp. Company Information
10.11.2 Tonix Pharmaceuticals Holding Corp. Introduction and Business Overview
10.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Products Offered
10.11.5 Tonix Pharmaceuticals Holding Corp. Recent Development
10.12 Verrica Pharmaceuticals Inc.
10.12.1 Verrica Pharmaceuticals Inc. Company Information
10.12.2 Verrica Pharmaceuticals Inc. Introduction and Business Overview
10.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Products Offered
10.12.5 Verrica Pharmaceuticals Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Poxviridae Infections Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Poxviridae Infections Drug Industrial Chain Analysis
11.4 Poxviridae Infections Drug Market Dynamics
11.4.1 Poxviridae Infections Drug Industry Trends
11.4.2 Poxviridae Infections Drug Market Drivers
11.4.3 Poxviridae Infections Drug Market Challenges
11.4.4 Poxviridae Infections Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Poxviridae Infections Drug Distributors
12.3 Poxviridae Infections Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of CJ-40011
Table 2. Major Company of 24a
Table 3. Major Company of BA-368
Table 4. Major Company of Others
Table 5. Global Poxviridae Infections Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Poxviridae Infections Drug Sales by Type (2018-2024) & (K Pcs)
Table 7. Global Poxviridae Infections Drug Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Poxviridae Infections Drug Sales by Type (2018-2024) & (US& Million)
Table 9. Global Poxviridae Infections Drug Market Share in Value by Type (2018-2024)
Table 10. Global Poxviridae Infections Drug Price by Type (2018-2024) & (USD/Pcs)
Table 11. Global Poxviridae Infections Drug Sales by Type (2024-2034) & (K Pcs)
Table 12. Global Poxviridae Infections Drug Sales Market Share in Volume by Type (2024-2034)
Table 13. Global Poxviridae Infections Drug Sales by Type (2024-2034) & (US$ Million)
Table 14. Global Poxviridae Infections Drug Sales Market Share in Value by Type (2024-2034)
Table 15. Global Poxviridae Infections Drug Price by Type (2024-2034) & (USD/Pcs)
Table 16. North America Poxviridae Infections Drug Sales by Type (2018-2024) & (K Pcs)
Table 17. North America Poxviridae Infections Drug Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Poxviridae Infections Drug Sales (K Pcs) by Type (2018-2024)
Table 19. Europe Poxviridae Infections Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Poxviridae Infections Drug Sales (K Pcs) by Type (2018-2024)
Table 21. Asia-Pacific Poxviridae Infections Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Poxviridae Infections Drug Sales (K Pcs) by Type (2018-2024)
Table 23. Latin America Poxviridae Infections Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Poxviridae Infections Drug Sales (K Pcs) by Type (2018-2024)
Table 25. Middle East and Africa Poxviridae Infections Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Poxviridae Infections Drug Sales by Company (2018-2024) & (K Pcs)
Table 27. Global Poxviridae Infections Drug Sales Share by Company (2018-2024)
Table 28. Global Poxviridae Infections Drug Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Poxviridae Infections Drug Revenue Share by Company (2018-2024)
Table 30. Global Market Poxviridae Infections Drug Price by Company (2018-2024) & (USD/Pcs)
Table 31. Global Poxviridae Infections Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Poxviridae Infections Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Poxviridae Infections Drug as of 2022)
Table 34. Date of Key Manufacturers Enter into Poxviridae Infections Drug Market
Table 35. Key Manufacturers Poxviridae Infections Drug Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Poxviridae Infections Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 38. Global Poxviridae Infections Drug Sales by Region (2018-2024) & (K Pcs)
Table 39. Global Poxviridae Infections Drug Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Poxviridae Infections Drug Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Poxviridae Infections Drug Sales Market Share in Value by Region (2018-2024)
Table 42. Global Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 43. Global Poxviridae Infections Drug Sales by Region (2024-2034) & (K Pcs)
Table 44. Global Poxviridae Infections Drug Sales Market Share in Volume by Region (2024-2034)
Table 45. Global Poxviridae Infections Drug Sales by Region (2024-2034) & (US$ Million)
Table 46. Global Poxviridae Infections Drug Sales Market Share in Value by Region (2024-2034)
Table 47. Global Poxviridae Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 48. Global Poxviridae Infections Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 49. Global Poxviridae Infections Drug Sales by Application (2018-2024) & (K Pcs)
Table 50. Global Poxviridae Infections Drug Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Poxviridae Infections Drug Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Poxviridae Infections Drug Sales Market Share in Value by Application (2018-2024)
Table 53. Global Poxviridae Infections Drug Price by Application (2018-2024) & (USD/Pcs)
Table 54. Global Poxviridae Infections Drug Sales by Application (2024-2034) & (K Pcs)
Table 55. Global Poxviridae Infections Drug Sales Market Share in Volume by Application (2024-2034)
Table 56. Global Poxviridae Infections Drug Sales by Application (2024-2034) & (US$ Million)
Table 57. Global Poxviridae Infections Drug Sales Market Share in Value by Application (2024-2034)
Table 58. Global Poxviridae Infections Drug Price by Application (2024-2034) & (USD/Pcs)
Table 59. North America Poxviridae Infections Drug Sales by Application (2018-2024) (K Pcs)
Table 60. North America Poxviridae Infections Drug Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Poxviridae Infections Drug Sales by Application (2018-2024) (K Pcs)
Table 62. Europe Poxviridae Infections Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Poxviridae Infections Drug Sales by Application (2018-2024) (K Pcs)
Table 64. Asia-Pacific Poxviridae Infections Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Poxviridae Infections Drug Sales by Application (2018-2024) (K Pcs)
Table 66. Latin America Poxviridae Infections Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Poxviridae Infections Drug Sales by Application (2018-2024) (K Pcs)
Table 68. Middle East and Africa Poxviridae Infections Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Poxviridae Infections Drug Sales by Country (2018-2024) & (K Pcs)
Table 70. North America Poxviridae Infections Drug Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Poxviridae Infections Drug Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Poxviridae Infections Drug Sales Market Share in Value by Country (2018-2024)
Table 73. North America Poxviridae Infections Drug Sales by Country (2024-2034) & (K Pcs)
Table 74. North America Poxviridae Infections Drug Sales Market Share in Volume by Country (2024-2034)
Table 75. North America Poxviridae Infections Drug Sales by Country (2024-2034) & (US$ Million)
Table 76. North America Poxviridae Infections Drug Sales Market Share in Value by Country (2024-2034)
Table 77. Europe Poxviridae Infections Drug Sales by Country (2018-2024) & (K Pcs)
Table 78. Europe Poxviridae Infections Drug Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Poxviridae Infections Drug Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Poxviridae Infections Drug Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Poxviridae Infections Drug Sales by Country (2024-2034) & (K Pcs)
Table 82. Europe Poxviridae Infections Drug Sales Market Share in Volume by Country (2024-2034)
Table 83. Europe Poxviridae Infections Drug Sales by Country (2024-2034) & (US$ Million)
Table 84. Europe Poxviridae Infections Drug Sales Market Share in Value by Country (2024-2034)
Table 85. Asia-Pacific Poxviridae Infections Drug Sales by Region (2018-2024) & (K Pcs)
Table 86. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Poxviridae Infections Drug Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Poxviridae Infections Drug Sales by Region (2024-2034) & (K Pcs)
Table 90. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Volume by Region (2024-2034)
Table 91. Asia-Pacific Poxviridae Infections Drug Sales by Region (2024-2034) & (US$ Million)
Table 92. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Value by Region (2024-2034)
Table 93. Latin America Poxviridae Infections Drug Sales by Country (2018-2024) & (K Pcs)
Table 94. Latin America Poxviridae Infections Drug Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Poxviridae Infections Drug Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Poxviridae Infections Drug Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Poxviridae Infections Drug Sales by Country (2024-2034) & (K Pcs)
Table 98. Latin America Poxviridae Infections Drug Sales Market Share in Volume by Country (2024-2034)
Table 99. Latin America Poxviridae Infections Drug Sales by Country (2024-2034) & (US$ Million)
Table 100. Latin America Poxviridae Infections Drug Sales Market Share in Value by Country (2024-2034)
Table 101. Middle East and Africa Poxviridae Infections Drug Sales by Country (2018-2024) & (K Pcs)
Table 102. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Poxviridae Infections Drug Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Poxviridae Infections Drug Sales by Country (2024-2034) & (K Pcs)
Table 106. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Volume by Country (2024-2034)
Table 107. Middle East and Africa Poxviridae Infections Drug Sales by Country (2024-2034) & (US$ Million)
Table 108. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Value by Country (2024-2034)
Table 109. Bavarian Nordic A/S Company Information
Table 110. Bavarian Nordic A/S Introduction and Business Overview
Table 111. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 112. Bavarian Nordic A/S Poxviridae Infections Drug Product
Table 113. Bavarian Nordic A/S Recent Development
Table 114. BioFactura, Inc. Company Information
Table 115. BioFactura, Inc. Introduction and Business Overview
Table 116. BioFactura, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 117. BioFactura, Inc. Poxviridae Infections Drug Product
Table 118. BioFactura, Inc. Recent Development
Table 119. CEL-SCI Corporation Company Information
Table 120. CEL-SCI Corporation Introduction and Business Overview
Table 121. CEL-SCI Corporation Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 122. CEL-SCI Corporation Poxviridae Infections Drug Product
Table 123. CEL-SCI Corporation Recent Development
Table 124. Chimerix, Inc. Company Information
Table 125. Chimerix, Inc. Introduction and Business Overview
Table 126. Chimerix, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 127. Chimerix, Inc. Poxviridae Infections Drug Product
Table 128. Chimerix, Inc. Recent Development
Table 129. China Biologic Products, Inc. Company Information
Table 130. China Biologic Products, Inc. Introduction and Business Overview
Table 131. China Biologic Products, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 132. China Biologic Products, Inc. Poxviridae Infections Drug Product
Table 133. China Biologic Products, Inc. Recent Development
Table 134. CJ HealthCare Corp. Company Information
Table 135. CJ HealthCare Corp. Introduction and Business Overview
Table 136. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 137. CJ HealthCare Corp. Poxviridae Infections Drug Product
Table 138. CJ HealthCare Corp. Recent Development
Table 139. EpiVax, Inc. Company Information
Table 140. EpiVax, Inc. Introduction and Business Overview
Table 141. EpiVax, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 142. EpiVax, Inc. Poxviridae Infections Drug Product
Table 143. EpiVax, Inc. Recent Development
Table 144. N & N Pharmaceuticals Inc. Company Information
Table 145. N & N Pharmaceuticals Inc. Introduction and Business Overview
Table 146. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 147. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product
Table 148. N & N Pharmaceuticals Inc. Recent Development
Table 149. SIGA Technologies, Inc. Company Information
Table 150. SIGA Technologies, Inc. Introduction and Business Overview
Table 151. SIGA Technologies, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 152. SIGA Technologies, Inc. Poxviridae Infections Drug Product
Table 153. SIGA Technologies, Inc. Recent Development
Table 154. Takeda Pharmaceutical Company Limited Company Information
Table 155. Takeda Pharmaceutical Company Limited Introduction and Business Overview
Table 156. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 157. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product
Table 158. Takeda Pharmaceutical Company Limited Recent Development
Table 159. Tonix Pharmaceuticals Holding Corp. Company Information
Table 160. Tonix Pharmaceuticals Holding Corp. Introduction and Business Overview
Table 161. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 162. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product
Table 163. Tonix Pharmaceuticals Holding Corp. Recent Development
Table 164. Verrica Pharmaceuticals Inc. Company Information
Table 165. Verrica Pharmaceuticals Inc. Introduction and Business Overview
Table 166. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 167. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product
Table 168. Verrica Pharmaceuticals Inc. Recent Development
Table 169. Key Raw Materials Lists
Table 170. Raw Materials Key Suppliers Lists
Table 171. Poxviridae Infections Drug Market Trends
Table 172. Poxviridae Infections Drug Market Drivers
Table 173. Poxviridae Infections Drug Market Challenges
Table 174. Poxviridae Infections Drug Market Restraints
Table 175. Poxviridae Infections Drug Distributors List
Table 176. Poxviridae Infections Drug Downstream Customers
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Poxviridae Infections Drug Product Picture
Figure 2. Global Poxviridae Infections Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Poxviridae Infections Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Poxviridae Infections Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of CJ-40011
Figure 6. Global CJ-40011 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of 24a
Figure 8. Global 24a Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of BA-368
Figure 10. Global BA-368 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Others
Figure 12. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Global Poxviridae Infections Drug Sales by Type (2018-2034) & (US$ Million)
Figure 14. Global Poxviridae Infections Drug Sales Market Share by Type in 2022 & 2034
Figure 15. North America Poxviridae Infections Drug Sales Market Share in Volume by Type in 2022
Figure 16. North America Poxviridae Infections Drug Sales Market Share in Value by Type in 2022
Figure 17. Europe Poxviridae Infections Drug Sales Market Share in Volume by Type in 2022
Figure 18. Europe Poxviridae Infections Drug Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Value by Type in 2022
Figure 21. Latin America Poxviridae Infections Drug Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Poxviridae Infections Drug Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Poxviridae Infections Drug Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Poxviridae Infections Drug Revenue in 2022
Figure 27. Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Hospital
Figure 29. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 30. Product Picture of Clinic
Figure 31. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 32. Product Picture of Others
Figure 33. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Global Poxviridae Infections Drug Sales by Application (2018-2034) & (US$ Million)
Figure 35. Global Poxviridae Infections Drug Sales Market Share by Application in 2022 & 2034
Figure 36. North America Poxviridae Infections Drug Sales Market Share in Volume by Application in 2022
Figure 37. North America Poxviridae Infections Drug Sales Market Share in Value by Application in 2022
Figure 38. Europe Poxviridae Infections Drug Sales Market Share in Volume by Application in 2022
Figure 39. Europe Poxviridae Infections Drug Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Value by Application in 2022
Figure 42. Latin America Poxviridae Infections Drug Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Poxviridae Infections Drug Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Poxviridae Infections Drug Manufacturing Cost Structure
Figure 47. Poxviridae Infections Drug Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries